* Results show strong signals of clinical responses in patients with advanced
cervical cancer who received up to 2 prior lines of therapy 


Oslo, Norway, November 7, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced results of additional
efficacy analysis of the interim results from its Phase 2 trial of VB10.16 in
combination with atezolizumab in advanced cervical cancer. 

"This additional analysis confirms our belief in VB10.16's competitive strength
and its potential to improve outcomes in patients with advanced cervical
cancer," said Michael Engsig, Chief Executive Officer of Nykode. "Our C-02 trial
enrolled heavily pre-treated patients with about one third having received three
or more prior treatments. The additional analysis shows an increased response
rate and competitive efficacy in patients receiving up to two prior therapies,
which increases our confidence in our vaccine platform's ability to induce
clinically relevant immune responses in patients with recurrent and metastatic
diseases. The data will help inform our clinical strategy as we further define
the patient population for our next study of VB10.16 in advanced cervical
cancer."

Interim data from 39 patients were announced in May 2022, please see here:
https://nykode.com/nykode-therapeutics-announces-positive-interim-results-from-i
ts-phase-2-trial-with-vb10-16-in-combination-with-immune-checkpoint-inhibitor-at
ezolizumab-in-advanced-cervical-cancer/. The trial enrolled patients pre-treated
with 1-5 lines of prior systemic therapy in recurrent or metastatic setting and
showed a 21% Objective Response Rate (ORR) on average across all lines. This new
analysis reviewed patient outcomes based on the number of previous lines of
systemic therapy and number of extrapelvic metastases, showing a robust clinical
benefit with partial and complete responses in 30% of patients treated with up
to two prior lines of therapy. The response rate was similarly higher in
patients with lower metastatic burden. A high disease control rate (DCR) was
observed across all patient groups. Importantly, the T cell responses continue
to show association with clinical outcomes. The data were reviewed as part of
the Company's presentation at the Credit Suisse Annual Healthcare Conference on
Tuesday, November 8, 2022. The presentation can be accessed in the Investors
section of the Company's website here:
https://nykode.com/investors/financial-reports-and-presentations/  


Results from the analysis showed:


Clinical response by prior systemic treatment line

No. of systemic treatments	     ORR	       DCR

1 (n=12)	                      17%               75%

2 (n=15)	                      40%               60%

3 (n=9)	                               0%           	55%

4 (n=1)	                               0%              100%

5 (n=2)	                               0%               50%



Clinical response based on number of extrapelvic metastases at baseline

No. of extrapelvic metastases	     ORR	       DCR

0 (n =4)	                      25%	       100%

1-5 (n=22)                            27%               73%

> 5 (n=13)                             8%               31%


About Cervical Cancer 
Cervical cancer is the fourth leading cause of cancer death in women worldwide
and is most frequently diagnosed between the ages of 35 and 44. Each year around
600,000 women are diagnosed with cervical cancer worldwide. Almost all cases are
caused by human papillomavirus (HPV) infection and HPV16 accounts for more than
half of all cervical cancer cases. Approximately 80% of patients with cervical
cancer have squamous cell carcinoma (arising from cells lining the bottom of the
cervix) and most other patients have adenocarcinomas (arising from glandular
cells in the upper cervix). Cervical cancer is often curable when detected early
and effectively managed, but treatment options are more limited in advanced
disease stages or when the cancer has spread.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase 2 trial
for the treatment of cervical cancer